Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients
Background: The systemic inflammatory response following severe COVID-19 is associated with poor outcomes. Several anti-inflammatory medications have been studied in COVID-19 patients. Xanthohumol (Xn), a natural extract from hop cones, possesses strong anti-inflammatory and antioxidative properties...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-02-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222014718 |
| _version_ | 1811177302486155264 |
|---|---|
| author | Wojciech Dabrowski Mariusz Gagos Dorota Siwicka-Gieroba Mariusz Piechota Jan Siwiec Magdalena Bielacz Katarzyna Kotfis Andrzej Stepulak Luiza Grzycka-Kowalczyk Andrzej Jaroszynski Manu LNG Malbrain |
| author_facet | Wojciech Dabrowski Mariusz Gagos Dorota Siwicka-Gieroba Mariusz Piechota Jan Siwiec Magdalena Bielacz Katarzyna Kotfis Andrzej Stepulak Luiza Grzycka-Kowalczyk Andrzej Jaroszynski Manu LNG Malbrain |
| author_sort | Wojciech Dabrowski |
| collection | DOAJ |
| description | Background: The systemic inflammatory response following severe COVID-19 is associated with poor outcomes. Several anti-inflammatory medications have been studied in COVID-19 patients. Xanthohumol (Xn), a natural extract from hop cones, possesses strong anti-inflammatory and antioxidative properties. The aim of this study was to analyze the effect of Xn on the inflammatory response and the clinical outcome of COVID-19 patients. Methods: Adult patients treated for acute respiratory failure (PaO2/FiO2 less than 150) were studied. Patients were randomized into two groups: Xn – patients receiving adjuvant treatment with Xn at a daily dose of 4.5 mg/kg body weight for 7 days, and C – controls. Observations were performed at four time points: immediately after admission to the ICU and on the 3rd, 5th, and 7th days of treatment. The inflammatory response was assessed based on the plasma IL-6 concentration, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP) and D-dimer levels. The mortality rate was determined 28 days after admission to the ICU. Results: Seventy-two patients were eligible for the study, and 50 were included in the final analysis. The mortality rate was significantly lower and the clinical course was shorter in the Xn group than in the control group (20% vs. 48%, p < 0.05, and 9 ± 3 days vs. 22 ± 8 days, p < 0.001). Treatment with Xn decreased the plasma IL-6 concentration (p < 0.01), D-dimer levels (p < 0.05) and NLR (p < 0.01) more significantly than standard treatment alone. Conclusion: Adjuvant therapy with Xn appears to be a promising anti-inflammatory treatment in COVID-19 patients. |
| first_indexed | 2024-04-10T22:59:33Z |
| format | Article |
| id | doaj.art-c9f1380dd47642b7b2cc0182fc95a337 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-10T22:59:33Z |
| publishDate | 2023-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-c9f1380dd47642b7b2cc0182fc95a3372023-01-14T04:25:40ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-02-01158114082Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patientsWojciech Dabrowski0Mariusz Gagos1Dorota Siwicka-Gieroba2Mariusz Piechota3Jan Siwiec4Magdalena Bielacz5Katarzyna Kotfis6Andrzej Stepulak7Luiza Grzycka-Kowalczyk8Andrzej Jaroszynski9Manu LNG Malbrain10First Department of Anesthesiology and Intensive Therapy Medical University of Lublin, Lublin, Poland,; Correspondence to: First Department of Anesthesiology and Intensive Therapy Medical University of Lublin, Jaczewskiego Street 8, 20-954 Lublin, Poland.Department of Cell Biology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Lublin, Poland,First Department of Anesthesiology and Intensive Therapy Medical University of Lublin, Lublin, Poland,Department of Anesthesiology and Intensive Therapy, Centre for Artificial Extracorporeal Kidney and Liver Support, Dr. W. Bieganski Regional Specialist Hospital, Łódź, Poland,Department of Pneumonology, Oncology and Allergology Medical University of Lublin, Poland,First Department of Anesthesiology and Intensive Therapy Medical University of Lublin, Lublin, Poland,Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, Szczecin, Poland,Department of Biochemistry and Molecular Biology, Medical University of Lublin, Poland,First Department of Medical Radiology, Medical University of Lublin, PolandCollegium Medicum, Jan Kochanowski University of Kielce, Poland,First Department of Anesthesiology and Intensive Therapy Medical University of Lublin, Lublin, Poland,Background: The systemic inflammatory response following severe COVID-19 is associated with poor outcomes. Several anti-inflammatory medications have been studied in COVID-19 patients. Xanthohumol (Xn), a natural extract from hop cones, possesses strong anti-inflammatory and antioxidative properties. The aim of this study was to analyze the effect of Xn on the inflammatory response and the clinical outcome of COVID-19 patients. Methods: Adult patients treated for acute respiratory failure (PaO2/FiO2 less than 150) were studied. Patients were randomized into two groups: Xn – patients receiving adjuvant treatment with Xn at a daily dose of 4.5 mg/kg body weight for 7 days, and C – controls. Observations were performed at four time points: immediately after admission to the ICU and on the 3rd, 5th, and 7th days of treatment. The inflammatory response was assessed based on the plasma IL-6 concentration, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP) and D-dimer levels. The mortality rate was determined 28 days after admission to the ICU. Results: Seventy-two patients were eligible for the study, and 50 were included in the final analysis. The mortality rate was significantly lower and the clinical course was shorter in the Xn group than in the control group (20% vs. 48%, p < 0.05, and 9 ± 3 days vs. 22 ± 8 days, p < 0.001). Treatment with Xn decreased the plasma IL-6 concentration (p < 0.01), D-dimer levels (p < 0.05) and NLR (p < 0.01) more significantly than standard treatment alone. Conclusion: Adjuvant therapy with Xn appears to be a promising anti-inflammatory treatment in COVID-19 patients.http://www.sciencedirect.com/science/article/pii/S0753332222014718XanthohumolCOVID-19CoronavirusCritically illInflammatory responseNeutrophil-to-lymphocyte ratio |
| spellingShingle | Wojciech Dabrowski Mariusz Gagos Dorota Siwicka-Gieroba Mariusz Piechota Jan Siwiec Magdalena Bielacz Katarzyna Kotfis Andrzej Stepulak Luiza Grzycka-Kowalczyk Andrzej Jaroszynski Manu LNG Malbrain Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients Biomedicine & Pharmacotherapy Xanthohumol COVID-19 Coronavirus Critically ill Inflammatory response Neutrophil-to-lymphocyte ratio |
| title | Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients |
| title_full | Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients |
| title_fullStr | Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients |
| title_full_unstemmed | Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients |
| title_short | Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients |
| title_sort | humulus lupus extract rich in xanthohumol improves the clinical course in critically ill covid 19 patients |
| topic | Xanthohumol COVID-19 Coronavirus Critically ill Inflammatory response Neutrophil-to-lymphocyte ratio |
| url | http://www.sciencedirect.com/science/article/pii/S0753332222014718 |
| work_keys_str_mv | AT wojciechdabrowski humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT mariuszgagos humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT dorotasiwickagieroba humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT mariuszpiechota humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT jansiwiec humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT magdalenabielacz humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT katarzynakotfis humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT andrzejstepulak humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT luizagrzyckakowalczyk humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT andrzejjaroszynski humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients AT manulngmalbrain humuluslupusextractrichinxanthohumolimprovestheclinicalcourseincriticallyillcovid19patients |